Our AI-based approach is designed to:
- Enhance R&D efficiencies
- Shorten development timelines
- Increase probability of success
![](/wp-content/uploads/2024/06/ai_approach_6_21_v2.webp)
Jul 16, 2024
BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual FilmVIEW RELEASE
Jun 25, 2024
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
May 28, 2024
BioXcel Therapeutics to Present at Jefferies Global Healthcare ConferenceVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Jul 26, 2024 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
1.15
CHANGE
-0.02 (-1.71%)